Taysha Gene Therapies, Inc. (TSHA) Revenue by Segment & Business Profile
Gene therapies for CNS monogenic diseases (e.g., TSHA-120, TSHA-102) was 100.0% of Taysha Gene Therapies, Inc.'s revenue, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TSHATaysha Gene Therapies, Inc.Follow TSHA — free
—
Price chart with a free account
- Market cap
- 1.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
What the company does
Taysha Gene Therapies, Inc. is a biotechnology company in the healthcare sector. Trailing twelve-month revenue: $5.5 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Clinical-stage developer
Taysha Gene Therapies, Inc. — questions
- What does Taysha Gene Therapies, Inc. do?
- Taysha Gene Therapies, Inc. is a biotechnology company in the healthcare sector. Trailing twelve-month revenue: $5.5 million as of 2026-06-30.
- How does Taysha Gene Therapies, Inc. make money?
- By the lines it reports in its SEC filings: Gene therapies for CNS monogenic diseases (e.g., TSHA-120, TSHA-102) 100.0% of revenue.
Every figure on this page comes from Taysha Gene Therapies, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.